



**UNITED STATES DEPARTMENT OF COMMERCE**  
**Patent and Trademark Office**  
**ASSISTANT SECRETARY AND COMMISSIONER**  
**OF PATENTS AND TRADEMARKS**  
Washington, D.C. 20231

AUG 27 1998

W. Scott McNees  
Cytogen Corporation  
600 College Road East  
Princeton, NJ 08540

Re: Patent Term Extension  
Application for  
U.S. Patent No. 5,162,504

Dear Mr. McNees:

A certificate under 35 U.S.C. § 156 is enclosed extending the term of U.S. Patent No. 5,162,504 for a period of 352 days.

Telephone inquiries regarding this communication should be directed to the undersigned at (703)306-3159.

Karin Tyson  
Legal Advisor  
Special Program Law Office  
Office of the Deputy Assistant Commissioner  
for Patent Policy and Projects

cc: Ronald L. Wilson, Director  
Health Assessment Policy Staff  
Office of Health Affairs (HFY-20)  
Food and Drug Administration  
5600 Fishers Lane, Room 15-22  
Rockville, MD 20857

RE: ProstaScint™ (capromab pendetide)  
FDA Docket No.: 97E-0107

kt

# UNITED STATES PATENT AND TRADEMARK OFFICE

## CERTIFICATE EXTENDING PATENT TERM UNDER 35 U.S.C. § 156

PATENT NO. : 5,162,504  
ISSUED : November 10, 1992  
INVENTOR(S) : Julius S. Horoszewicz  
PATENT OWNER : Cytogen Corporation

This is to certify that there has been presented to the

### COMMISSIONER OF PATENTS AND TRADEMARKS

an application under 35 U.S.C. § 156 for an extension of the patent term. Since it appears that the requirements of the law have been met, this certificate extends the term of the patent for the period of

352 days

from November 10, 2009, the original expiration date of the patent, subject to the provisions of 35 U.S.C. § 41(b), with all rights pertaining thereto as provided by 35 U.S.C. § 156(b).



I have caused the seal of the Patent and Trademark Office to be affixed this 27th day of August 1998.

  
Bruce A. Lehman

Assistant Secretary of Commerce and  
Commissioner of Patents and Trademarks